Anavex Life Sciences Corp (AVXL)

[Investor2014]

Good point.
Dose and S1R mRNA expression is likely correlated too, but as you imply not necessarily in a linear fashion as there may be several confounding factors.

the company seems to be shifting main focus from drug concentration correlation to the mRNA concentration correlation

It casts the mind back to the P2a AD outliers, some doing great on next to no A2-73 concentration and others not so well on "therapeutic window" concentrations. This was all rather obscure and never to my knowledge explained.

Maybe the Therapeutic Window concentration concept can be revised if it can be shown that S1R mRNA expression levels has a direct correlation to efficacy. Then we would indeed have a new upstream biomarker covering potentially a broad spectrum of CNS indications and maybe even more.

If so this biomarker needs to be compartmentalised by tissue types, as it is know S1R expression differs in different parts of the body. We then would need to establish normal range for each and adjust dose until met.